S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Baxter Submits Application for U.S. FDA Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A (2014/12/1)|
|Baxter Presents Additional Data from Pivotal Study of BAX 855, Extended Half-Life Investigational Recombinant FVIII Based on ADVATE for Hemophilia A (2015/2/11)|
|Baxter Provides Progress Update on Gene Therapy Program, Including Phase I/II Clinical Trial of BAX 335, Investigational Gene Therapy Treatment for Hemophilia B (2015/2/12)|
|Baxter Selects Bannockburn, Ill., Facility as Location for Baxalta Global Headquarters (2015/2/23)|
|Baxter Announces Filing of Form 10 Registration Statement in Connection with Planned Spin off of Biopharmaceuticals Business (2014/12/10)|
|Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics (2014/12/15)|
|Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment for Von Willebrand Disease (2014/12/22)|
|Baxter to Present at 33rd Annual J.P. Morgan Healthcare Conference (2014/12/18)|
|Baxter to Present at Barclay’s Global Healthcare Conference (2015/2/19)|
|Baxter Declares Quarterly Dividend (2015/2/17)|
Click above to view more mutual fund data and stats for bax - Baxter International Inc.